tbuckley/cabot-search huggingface dataset:
Abstract 864: Correlates of mammography screening practice among immigrant women in Southern California
Authors: Magda A. Shaheen, Blanca Caro, Yasser Aman, Mahtash Esfandiari, Judie Hulett, Osman Galal
Journal: Cancer Research (2010)

Abstract Introduction: Breast cancer (BC) is the most commonly diagnosed cancer among women in the United States. Immigrant underrepresented women are facing many challenges and barriers to knowledge, access to health care and preventive services. Few studies have examined factors associated with mammography screening among immigrant women in Southern California. Purpose: We examined factors associated with mammography screening among immigrant women in Southern California. Methods: A cross-sectional study of 517 immigrant women aged 40 years and older. The instrument included constructs from the Health Belief Model. The survey was conducted using a self administered questionnaire in the women's preferred language. The outcome variables were the percentage of women ages 40 and older who ever received a mammogram and the percentage of women who received a mammogram within the past year. Independent variables were demographics, frequency of visits to health care provider, and scores of the following variables: knowledge of BC symptoms and BC risk factors, perceived benefits, perceived health motivation and perceived barriers to obtaining a mammogram. We analyzed data using SPSS 15. Results: of the 517 women, 50% were Iranian, 15% were Arab, and 21% were Asian/South Asian. Twenty eight percent had family history of BC, 63% had a friend diagnosed with BC, and 47% had yearly visit to the health care provider. Ever had a mammogram was reported by 88% of the women and 73% reported they had mammogram within the last 12 months. Participants had low knowledge of BC symptoms (mean score=7, Standard Deviation [SD]=3.5, range=1-13) and low knowledge of BC risk factors (mean score=8, SD=3.6, range=1-21). Women showed high health motivation (mean score=4.4, SD=0.6, range=1-5) and low barriers (mean score=2.4, SD=0.6, range=1-5). Predictors of ever had a mammogram were age, having a friend who was diagnosed with BC, and having a high score of health motivation. Factors associated with having a mammogram within the past year were having frequent visits to the health care provider, having a higher score in knowledge of BC symptoms, and having a lower score of perceived barriers to obtaining a mammogram. Conclusions: The findings indicated that health care provider may influence the BC screening among immigrant women. There is a need for a culturally sensitive educational intervention to enhance the knowledge and awareness related to BC. This intervention can be provided through the health care provider and through the social support and family groups. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 864.
PWE-036 What is the survival of patients with oesophageal cancer following palliative stenting?
Authors: S R Whiteoak, R Frost, J Loehry, K Smith, B Colleypriest
Journal: Gut (2012)

<h3>Introduction</h3> Following the treatment of patients with soft tissue sarcomas (STS) that are not metastatic at presentation, the high risk for local and systemic disease recurrence necessitates post-treatment surveillance. Systemic recurrence is most often detected in the lungs. The most appropriate surveillance frequency and modality remain unknown and, as such, clinical practice is highly varied. We plan to assess the feasibility of conducting a multi-centre randomised controlled trial (RCT) that will evaluate the effect on overall 5-year survival of two different surveillance frequencies and imaging modalities in patients with STS who undergo surgical excision with curative intent. <h3>Methods and analysis</h3> The Surveillance After Extremity Tumor Surgery trial will be a multi-centre 2×2 factorial RCT. Patients with non-metastatic primary Grade II or III STS treated with excision will be allocated to one of four treatment arms1: chest radiograph (CXR) every 3 months for 2 years2; CXR every 6 months for 2 years3; chest CT every 3 months for 2 years or4 chest CT every 6 months for 2 years. The primary outcome of the pilot study is the feasibility of a definitive RCT based on a combination of feasibility endpoints. Secondary outcomes for the pilot study include the primary outcome of the definitive trial (overall survival), patient-reported outcomes on anxiety, satisfaction and quality of life, local recurrence-free survival, metastasis-free survival, treatment-related complications and net healthcare costs related to surveillance. <h3>Ethics and dissemination</h3> This trial received provisional ethics approval from the McMaster/Hamilton Health Sciences Research Ethics Board on 7 August 2019 (Project number 7562). Final ethics approval will be obtained prior to commencing patient recruitment. Once feasibility has been established and the definitive protocol is finalised, the study will transition to the definitive study. <h3>Trial registration</h3> NCT03944798; Pre-results.
Closure of a gastrocutaneous fistula by a tulip-bundle technique
Authors: F. Perri, M. Gentile, D. Scimeca, F. Terracciano, A. Merla, F. Spirito, A. Andriulli
Journal: Endoscopy (2011)

A 79-year-old woman developed a gastrocutaneous fistula after removal of a 20-Fr percutaneous endoscopic gastrostomy (PEG) tube. During endoscopy, the gastric orifice was identified ([Fig. 1]) and an unsuccessful attempt was made to close the fistula using endoclips. Therefore, we used a tulip-bundle technique [1], which is a variation of the combined endoloop and endoclip method that was originally described for the closure of large iatrogenic perforations [2] [3].
Abstract 2973: Adhesion of tumor cells to ECM microarrays identifies novel ECM interactions in metastasis
Authors: Nathan E. Reticker-Flynn, David F. Braga Malta, Monte M. Winslow, Mary J. Xu, John M. Lamar, Richard O. Hynes, Tyler E. Jacks, Sangeeta N. Bhatia
Journal: Cancer Research (2012)

Abstract Extracellular Matrix (ECM) interactions play an essential role in all phases of tumorigenesis and metastasis. Here, we report a novel ECM microarray platform for investigating the combinatorial effects of ECM adhesion on cancer metastasis. This platform is composed of micropatterned spots of nearly 800 unique ECM combinations, and can be used to measure cellular adhesion, proliferation, marker expression, or any other phenotypic responses that can be queried by microscopy. Using a genetic model of lung adenocarcinoma (KrasLSL-G12D/+;p53flox/flox), we tested the adhesion of cell lines derived from tumors throughout the stages of tumor progression. We found that the adhesion profiles of primary tumors and their metastases could be distinguished by Euclidian clustering whereas gene expression profiles of the same cells could not. In particular, we identified combinations of ECM molecules that exhibited preferential adhesion to either the metastatic or primary tumor cell lines. Histological examination of tissues from mice bearing the autochthonous tumors confirmed that the primary tumor-associated molecules are present in the lungs but not the sites of metastases. Conversely, metastasis-associated ECM molecules were not present in the primary tumors, but were expressed at the metastatic sites. From the known integrin-ECM interactions, we then identified several integrins as playing a functional role in ECM interactions during lung cancer metastasis. Flow cytometry confirmed higher expression of these candidates on the cell surface of the metastatic lines than the primary lines. Knockdown of integrin expression in the metastatic cells by shRNAs reduced the adhesion of the cells to the cognate ECM molecules in vitro, confirming a functional role in our phenotypic assay. Additionally, abrogation of cell-ECM interactions through inhibition of contact between the metastasis-associated molecules and the receptors on the metastatic cells prevented metastases from seeding in vivo. Thus, ECM microarrays offer a novel platform for the phenotypic characterization of tumor cells from different stages of tumor progression, identification of key ECM interactions, and the identification of potential therapeutic targets in cancer metastasis. In the future, we will apply the ECM Microarrays for the stratification of patients to assist in diagnostics and treatment guidance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2973. doi:1538-7445.AM2012-2973
PTU-184 Restrictive Versus Liberal Blood Transfusion For Acute Upper Gastrointestinal Bleeding: Cluster Randomised Feasibility Trial
Authors: V Jairath, B Kahan, A Gray, C Dore, K Palmer, S Travis, R Logan, T Walsh, M Murphy
Journal: Gut (2014)

<h3>Introduction</h3> Transfusion thresholds for upper gastrointestinal bleeding (UGIB) are controversial. Observational studies suggest associations between liberal red blood cell (RBC) transfusion and adverse outcome, and a recent trial reported increased mortality following liberal transfusion. <h3>Methods</h3> Pragmatic cluster randomised trial to evaluate the feasibility and safety of implementing a restrictive (transfusion when haemoglobin (Hb) &lt;8g dL) versus liberal (transfusion when Hb &lt;10 g/dL) RBC transfusion policy for UGIB. Hospitals were randomised to a policy which was implemented through a multi-faceted educational intervention targeting all staff caring for patients with UGIB. All adult patients were eligible to participate, regardless of co-morbidity; the only exclusion criterion was exsanguinating haemorrhage. Feasibility and exploratory clinical outcomes were recorded up to day 28. <h3>Results</h3> 936 patients were enrolled in 6 hospitals. The consent rate for follow up was higher in the liberal arm (62% vs. 55%; P = 0.04). There were some baseline imbalances, however the Rockall and Blatchford scores were identical between arms as was the prevalence of ischaemic heart disease (IHD) (14% liberal arm vs. 15% restrictive arm). Protocol adherence was 96% in the restrictive arm vs. 83% in the liberal arm. In patients with a Hb &lt;12 g/dL, the Hb at discharge was 10.7 g/dL (sd 1.2) in the liberal arm vs. 10.1 g/dL (sd 1.3) in the restrictive arm (P = 0.05). In the restrictive arm there was a 13% absolute reduction in the proportion of patients receiving RBCs (95% CI for difference in% -35 to 11, P = 0.23) with a mean of 0.8 fewer RBC units transfused (95% CI: -1.9 –to 0.3, P = 0.12). Clinical outcomes were better in the restrictive arm, although differences were not statistically significant (28-day mortality, 7% liberal vs. 5% restrictive, adjusted difference in% = -1.3, 95% CI: -8.0 to 5.5, P = 0.63; further bleeding, 9 vs. 5%, P = 0.29; serious adverse events, 22% vs. 18%, P = 0.48). In the subgroup with IHD, there was a large observed difference for mortality (12% restrictive arm (n = 6) vs. 3% liberal arm (n = 2); interaction P = 0.11). <h3>Conclusion</h3> The protocol was feasible and generated clinically important differences in the level of anaemia and RBC exposure. There was a consistent trend towards fewer complications in the restrictive arm, apart from the increased mortality observed in patients with IHD, which could in part be explained by imbalances in baseline risk. A large trial is required to clarify the risk-benefit balance before advocating restrictive RBC transfusion for all patients with UGIB. <h3>Disclosure of Interest</h3> None Declared.
AB0899 Hip involvement and its predicting factors in turkish ankylosing spondylitis: A single center experience:
Authors: I. Sari, D. Solmaz, S. Akar, P. Cetin, M. Birlik, F. Onen, N. Akkoc
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Hip involvement is present in 25 to 35 percent of patients with ankylosing spondylitis (AS) and is associated with higher degrees of disability and a worse prognosis. Thus, early detection of hip arthritis is important for future prevention of disability. <h3>Objectives</h3> To predict the demographical, clinical and laboratory parameters related with hip involvement. <h3>Methods</h3> This study included 262 AS patients. Clinical, laboratory, and radiographic data were retrospectively analyzed. Bath AS radiology index (BASRI) hip index was used to define the radiological hip involvement. We also assessed Bath AS Functional Index (BASFI), Bath AS disease activity index (BASDAI), and Bath AS metrology index (BASMI). The AS disease activity scores (ASDAS) of the patients were calculated. Based on the radiographs, a score of at least 2 was used for the definition of hip joint involvement. Logistic regression analyses were used to investigate the factors associated with the severity of hip arthritis. <h3>Results</h3> There were 262 patients (men, 201, 76.7%). Mean age and disease duration of the patients were 44±11 and 19±10 years respectively. 57 patients (21.8%) had radiographic hip involvement and 135 (54.2%) patients had syndesmophytes. Comparison of radiological hip arthritis patients with no hip disease showed that hip arthritis group had significantly higher disease duration, male predominance, reported higher frequency of groin pain, increased BASMI, BASFI, CRP and ASDAS-CRP values (<i>P</i> &lt;0.05). On the other hand, intermalleolar distance was significantly shorter and frequency of syndesmophytes were significantly higher in patients without hip arthritis group compared to those with hip arthritis patients (<i>P</i>&lt;0.05). Other demographic and clinical features of groups are presented in table 1. Male sex, disease duration, presence of syndesmophytes, history of groin pain, inter-malleolar distance, BASMI, BASFI, CRP, ASDAS-CRP showed significant correlations with BASRI-hip (<i>P</i>&lt;0.05, r =0.1, 0.2, 0.2, 0.2, -0.5, 0.4, 0.3, 0.3 and 0.2 respectively). Regression analysis showed that only male sex, history of groin pain, intermalleolar distance, and BASFI variables were predicting the radiological hip involvement (beta =32.3, 5, 0.93, and 1.42). <h3>Conclusions</h3> Hip involvement is present about one out of the five patients with AS and is associated with male sex, impaired functioning reflected by higher BASFI scores, limitation of hip movement assessed by intermalleolar distance and clinical history of groin pain. <h3>Disclosure of Interest</h3> None Declared
Abstract 3090: Inhibition of p53 DNA binding function by the MDM2 acidic domain
Authors: Brittany L. Cross, Qain Cheng, Baozong Li, Zhi-Min Yuan, Jiandong Chen
Journal: Cancer Research (2011)

Abstract MDM2 is an important regulator of p53, acting in part by promoting p53 ubiquitination. However, MDM2 has also been implicated in regulation of p53 through ubiquitination-independent mechanisms. Here we show that MDM2 inhibits p53 DNA binding activity in vitro and in vivo. MDM2 binding promotes p53 to adopt a mutant-like conformation, losing reactivity to antibody Pab1620, while exposing the Pab240 epitope. The acidic domain of MDM2 is required to induce p53 conformational change and inhibit p53 DNA binding, possibly by interacting with the p53 DNA binding domain. ARF binding to the MDM2 acidic domain restores p53 wild type conformation and rescues DNA binding activity. Furthermore, histone methyl transferase SUV39H1 binding to the MDM2 acidic domain also restores p53 wild type conformation and allows p53-MDM2-SUV39H1 complex to bind DNA. These results provide further evidence for an ubiquitination-independent mechanism of p53 regulation by MDM2, and reveal how MDM2-interacting repressors gain access to p53 target promoters and repress transcription. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3090. doi:10.1158/1538-7445.AM2011-3090
Abstract 1716: BRCA1 expression modulates apoptosis and survival in response to retinoic acid in breast cancer cells
Authors: Itay Pickholtz, Moshe Z. Papa, Ronit I. Yarden
Journal: Cancer Research (2010)

Abstract The vitamin A metabolite retinoic acid (RA) plays key roles in development, cell proliferation and differentiation. RA derivatives also display anti-cancinogenic activities. The different physiological effects of RA are mediated by retinoic acid receptors (RARs) and retinoid-X receptos (RXRs) that are transcription factors and members of the nuclear hormone receptor superfamily. Transcriptional activation by RA trigger cell cycle arrest, differentiation and apoptosis in certain tissues and cell types but in other tissues RA appear to promote rather than inhibit cell survival. Recently, RA derivatives were shown to bind and activate the orphan nuclear hormone receptor, peroxisome proliferator-activated β/δ (PPARβ/δ) when it hetrodimerizes with RXR. The partitioning of RA between the RAR and PPARβ/δ receptors is regulated by the balance between two intracellular lipid binding proteins: cellular retinoic acid binding protein II (CRABPII) and fatty acid binding protein 5 (FABP5). While CRABP-II delivers RA to RAR-RXR and facilitates anti-proliferative effects, FABP5 shuttles RA to PPARβ/δ-RXR and promotes pro-survival functions. Interestingly, the breast and ovarian tumor suppressor, BRCA1 and RA share the ability to direct cell-cycle arrest and apoptosis, and both BRCA1 and RA regulate transcription and chromatin structure. We hypothesize that BRCA1 and RA pathways work in concert to inhibit cell growth in breast cancer cells. We found that the inhibitory effects of all-trans RA (ATRA) and 9-cisRA correlate with BRCA1 expression. Both RA derivatives inhibited BRCA1-proficient MCF7 breast cancer cells growth by inducing apoptosis. ATRA and 9-cisRA did not inhibit the growth of BRCA1-null or BRCA1-silenced breast cancer cells despite similar levels of RA receptors (RAR and RXR) expression. We show here that in BRCA1-proficient cells, the FABP5/CRABP-II ratio is constant facilitating apoptotic cell death, while in BRCA1-deficient cells FABP5/CRABP-II ratio is elevated, and coincides with increased phosphorylation of the pro-survival factor, AKT, supporting RA-mediated cell survival. Additional apoptotic and cell cycle genes were differentially regulated between BRCA1-deficient and proficient cells in response to RA. However, RA-induction of the metabolic enzyme CYP26 gene expression was not altered between BRCA1-deficient and proficient cells, suggesting the cooperation between RA and BRCA1 is affecting cell proliferation but not necessarily all spectrum of RA signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1716.
BCPT: Participant Update
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article BCPT: Participant Update Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 13, 6 July 1994, Page 962, https://doi.org/10.1093/jnci/86.13.962 Published: 06 July 1994
Clinical Importance of Gastric Varices
Authors: Samuel Karr, George T. Wohl
Journal: New England Journal of Medicine (1960)

GASTRIC varices are being seen increasingly often in the patient presenting acute gastrointestinal hemorrhage. This increased frequency is associated with a greater number of cirrhotic patients found in hospital practice. In the cirrhotic patient hemorrhage is usually thought to be secondary to esophageal varices although peptic ulcer and cancer are always considered in the differential diagnosis. The erroneous diagnosis of 3 cases as gastric carcinoma when the underlying etiology was gastric varices led us to a review of this problem.Although it is true that many patients with early cirrhosis have no portal hypertension the caliber and extent of the . . .
AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R<sup>2</sup>) versus placebo plus rituximab.
Authors: John Leonard, John G. Gribben, Marek Trněný, Phillip Scheinberg, Kensei Tobinai, Nathan Hale Fowler, Nurgul Kilavuz, Pierre Fustier, Barbara Amoroso
Journal: Journal of Clinical Oncology (2015)

TPS8603 Background: The immunomodulatory drug, lenalidomide (Revlimid), has both anti-inflammatory and antiangiogenic properties. In preclinical studies, the immunological function of tumor-infiltrating lymphocytes is reduced in patients with follicular lymphoma (FL); lenalidomide can restore this response (Ramsay, Blood, 2009). In a phase 2 trial of frontline lenalidomide + rituximab (R2), the overall response rate (ORR) reached 90% (Fowler, Lancet Oncol, 2014) in iNHL patients; in a second study, patients with FL achieved 93% ORR (Martin, ICML, 2013). After treatment with R2 in phase 2 investigations, patients with R/R iNHL achieved clinical responses: ORRs of 73% (36% complete response [CR]) in R/R FL (Leonard, ASCO 2012 oral presentation), and 80% (55% CR) in marginal zone lymphoma (MZL; Raderer, EHA 2014 oral presentation) patients. Based on the results of these preclinical and phase 2 studies, further investigation of R2 in iNHL is warranted. Methods: This multicenter, double-blind, phase 3, randomized study (AUGMENT) is designed to evaluate the efficacy and safety of R2 versus placebo + rituximab (P+R) in patients with R/R iNHL. Eligibility criteria for patients include: grade 1, 2, or 3a FL or MZL; previous treatment with systemic therapy; considered refractory to or relapsed after last treatment; rituximab-sensitivity if prior rituximab therapy was administered; presentation of ≥ 1 measurable lesion; and adequate function in bone marrow, liver, and kidneys. An estimated 350 patients will be randomized 1:1 to either experimental or control groups. Patients enrolled in the R2 experimental study arm will receive lenalidomide (20 mg/day; days 1 to 21 up to 12 cycles) + rituximab (375 mg/m2; days 1, 8, 15, 22 of cycle 1 and day 1 of cycles 2 to 5) in 28-day cycles. Patients in the control study arm will receive P+R (375 mg/m2) following the same schedule. Progression-free survival is the primary endpoint, and key secondary endpoints will include rate of durable CR, overall survival, ORR, safety, and time to next anti-lymphoma treatment. Patients are currently being enrolled for this trial (NCT01938001). Clinical trial information: NCT01938001.